NVZMY - Novozymes A/S

Other OTC - Other OTC Delayed Price. Currency in USD
47.27
+0.35 (+0.74%)
As of 2:34PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close46.92
Open47.11
Bid0.00 x 0
Ask0.00 x 0
Day's Range46.90 - 47.32
52 Week Range40.38 - 55.84
Volume3,626
Avg. Volume12,925
Market Cap13.549B
Beta (3Y Monthly)0.46
PE Ratio (TTM)27.92
EPS (TTM)1.69
Earnings DateN/A
Forward Dividend & Yield0.76 (1.62%)
Ex-Dividend Date2019-02-28
1y Target Est57.08
Trade prices are not sourced from all markets
  • Novozymes CEO: Oil price and bioenergy price are not corr...
    CNBC Videos9 months ago

    Novozymes CEO: Oil price and bioenergy price are not corr...

    There is so much opportunity in the market place, says Peder Holk Neilsen, CEO of Novozymes.

  • A Closer Look At Novozymes A/S's (CPH:NZYM B) Impressive ROE
    Simply Wall St.26 days ago

    A Closer Look At Novozymes A/S's (CPH:NZYM B) Impressive ROE

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • Reuterslast month

    UPDATE 1-European stocks head for best week in 2 months, Sanofi jumps

    European stocks were on course to notch their best weekly performance in two months on Friday as a jump in shares of French pharma giant Sanofi added to the positive mood created by expectations of more moves by central banks to stir growth. France's CAC 40 outperformed its peers with a 1.2% rise, helped by a 4.5% jump in Sanofi after the company appointed Swiss rival Novartis' executive Paul Hudson as its new boss.

  • Why You Should Like Novozymes A/S’s (CPH:NZYM B) ROCE
    Simply Wall St.2 months ago

    Why You Should Like Novozymes A/S’s (CPH:NZYM B) ROCE

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we'll evaluate Novozymes A/S (CPH:NZYM B) to determine whether it could have potential as an inve...

  • What Does Novozymes A/S's (CPH:NZYM B) P/E Ratio Tell You?
    Simply Wall St.3 months ago

    What Does Novozymes A/S's (CPH:NZYM B) P/E Ratio Tell You?

    Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll apply a basic P/E ratio analysis to Novozymes A/S's (CPH:NZYM B), to help you decide if the stock is worth further research...

  • Novozymes gets more partners for bio-agriculture arm beyond Bayer
    Reuters3 months ago

    Novozymes gets more partners for bio-agriculture arm beyond Bayer

    Novozymes has signed up two new partners for its biological agriculture business (BioAg), adding to its previously exclusive partnership with German chemicals giant Bayer in a drive to boost growth. The Danish company is the world's largest maker of industrial enzymes and with BioAg produces microbes such as bacteria and fungi to protect plants from pests and help them to grow faster. It will continue a close innovation and commercial partnership with Bayer within corn and soy, Novozymes said late on Thursday, as it presented two new partners - Univar Solutions and UPL.

  • With 3.4% Earnings Growth, Did Novozymes A/S (CPH:NZYM B) Outperform The Industry?
    Simply Wall St.4 months ago

    With 3.4% Earnings Growth, Did Novozymes A/S (CPH:NZYM B) Outperform The Industry?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Analyzing Novozymes A/S's (CPH:NZYM B) track record of past performance is a valuable exercise for investors. It enables us t...

  • What Kind Of Shareholders Own Novozymes A/S (CPH:NZYM B)?
    Simply Wall St.4 months ago

    What Kind Of Shareholders Own Novozymes A/S (CPH:NZYM B)?

    A look at the shareholders of Novozymes A/S (CPH:NZYM B) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely,Read More...

  • ACCESSWIRE11 months ago

    Novozymes A/S Class B to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Novozymes A/S Class B (OTC PINK: NVZMY ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 10, 2018 at 9:00 AM Eastern ...

  • CNBC11 months ago

    Biotech firm Novozymes sinks 3% after earnings miss

    The factors that are pulling in our business are slightly different from what we expected," Peder Holk Nielsen, the CEO of Novozymes told "Squawk Box Europe" on Friday. Earnings before interest and tax (EBIT) for the quarter came in at 957 million Danish krone ($147 million) with its household care sector showing particular weakness. Shares of global biotechnology company Novozymes slumped Friday morning after reporting second-quarter earnings that missed analysts' expectations.